ViroLogic Enters Tenth Pharmaceutical Company Agreement to Assess New Anti-HIV Drugs

Apr 24, 2001, 01:00 ET from ViroLogic, Inc.

    SOUTH SAN FRANCISCO, Calif., April 24 /PRNewswire Interactive News
 Release/ -- ViroLogic, Inc. (Nasdaq:   VLGC) today announced an agreement with
 DuPont Pharmaceuticals Company to assist DuPont Pharmaceuticals in the
 evaluation of new anti-HIV agents in development.  DuPont Pharmaceuticals will
 use ViroLogic's drug resistance testing technology to evaluate drug activity
 against HIV strains that are resistant to currently available drugs.  This is
 ViroLogic's tenth such collaboration with a leading biopharmaceutical company
 in this disease area.
     ViroLogic now has collaborations with Abbott Laboratories, Agouron
 Pharmaceuticals, Bristol-Myers Squibb, Chiron Corporation, DuPont
 Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Merck & Co., Hoffmann-La
 Roche and Vertex Pharmaceuticals.
     Under the terms of the agreement, ViroLogic's phenotypic and genotypic
 drug resistance assays, PhenoSense(TM) HIV and GeneSeq(TM) HIV, will be used
 to evaluate the effectiveness of DuPont Pharmaceuticals' investigational drugs
 in development.
     As recommended by the U.S. Food and Drug Administration, biopharmaceutical
 companies are using HIV resistance testing technology to enhance
 next-generation HIV drug development.  There are 15 approved HIV drugs and
 another 40 new drugs in the pipeline, all of which will require resistance
 testing in their development.
     "To date, resistance assays have been applied in the later stages of drug
 development, which we see as about a $70 million market with attractive growth
 prospects," said Bill Young, ViroLogic's Chairman and Chief Executive Officer.
 "However, lead drug targets can be screened for resistance profiles much
 earlier in the development phase, and assays can also be applied in early
 stage drug discovery.  The market potential here is significantly larger than
 the late stage application, and the technology exists to immediately implement
 the assay.  Use of our assays in earlier stages could save pharmaceutical
 companies significant time and money."
     ViroLogic expects to grow the pharmaceutical segment of its business by
 applying its technology and expertise to other serious viral diseases where
 resistance is a key obstacle to treatment.
     "The growing number of hepatitis therapies in development also presents a
 very attractive opportunity, which we are proactively targeting," added Young.
 "ViroLogic is the only viral resistance company that provides the full range
 of resistance testing used in drug development today and is 'neutral' in that
 it does not develop its own drugs and does not intend to compete with the
 pharmaceutical companies.  These factors make ViroLogic an ideal provider of
 drug discovery and drug development services.  We feel that this is a platform
 we can grow by penetrating the earlier stages of drug discovery and
 development as well as by offering complimentary technologies."
 
     About ViroLogic
     ViroLogic is a biotechnology company advancing the fields of
 individualized medicine and pharmacogenomics, helping to make them realities
 in healthcare around the world today.  The Company discovers, develops and
 markets innovative products to guide and improve treatment of serious viral
 diseases such as AIDS and hepatitis.  Its industry-leading expertise in
 virology, molecular biology, clinical research, engineering, information
 systems, and quality assurance has resulted in technology to assess drug
 resistance and susceptibility in viruses that cause these diseases, which
 affect millions of people worldwide.
     The Company's current products are designed to optimize HIV/AIDS treatment
 regimens, providing physicians with important information to help select
 appropriate drugs for their patients and leading to better outcomes and
 reduced costs.  These products are also being used by nearly every major
 pharmaceutical company working to develop new and improved antiviral
 therapeutics that can be more effective in an increasingly drug-resistant
 environment.
     Certain statements in this press release are forward-looking, including
 statements relating to laboratory testing agreements with pharmaceutical
 companies.  These forward-looking statements are subject to risks and
 uncertainties and other factors, which may cause actual results to differ
 materially from the anticipated results or other expectations expressed in
 such forward-looking statements.  These risks and uncertainties include, but
 are not limited to, whether PhenoSense(TM) and GeneSeq(TM) testing will
 achieve market acceptance, whether payers will authorize reimbursement for our
 products, whether we will be able to expand our sales and marketing
 capabilities, whether we encounter problems or delays in automating our
 process, whether we successfully introduce new products using our
 PhenoSense(TM) technology, whether intellectual property underlying our
 PhenoSense(TM) technology is adequate, whether we are able to build brand
 loyalty, and other risks and uncertainties detailed from time to time in our
 reports to the Securities and Exchange Commission, including our report on
 Form 10-K for the year ended December 31, 2000.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X79238467
 
 

SOURCE ViroLogic, Inc.
    SOUTH SAN FRANCISCO, Calif., April 24 /PRNewswire Interactive News
 Release/ -- ViroLogic, Inc. (Nasdaq:   VLGC) today announced an agreement with
 DuPont Pharmaceuticals Company to assist DuPont Pharmaceuticals in the
 evaluation of new anti-HIV agents in development.  DuPont Pharmaceuticals will
 use ViroLogic's drug resistance testing technology to evaluate drug activity
 against HIV strains that are resistant to currently available drugs.  This is
 ViroLogic's tenth such collaboration with a leading biopharmaceutical company
 in this disease area.
     ViroLogic now has collaborations with Abbott Laboratories, Agouron
 Pharmaceuticals, Bristol-Myers Squibb, Chiron Corporation, DuPont
 Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Merck & Co., Hoffmann-La
 Roche and Vertex Pharmaceuticals.
     Under the terms of the agreement, ViroLogic's phenotypic and genotypic
 drug resistance assays, PhenoSense(TM) HIV and GeneSeq(TM) HIV, will be used
 to evaluate the effectiveness of DuPont Pharmaceuticals' investigational drugs
 in development.
     As recommended by the U.S. Food and Drug Administration, biopharmaceutical
 companies are using HIV resistance testing technology to enhance
 next-generation HIV drug development.  There are 15 approved HIV drugs and
 another 40 new drugs in the pipeline, all of which will require resistance
 testing in their development.
     "To date, resistance assays have been applied in the later stages of drug
 development, which we see as about a $70 million market with attractive growth
 prospects," said Bill Young, ViroLogic's Chairman and Chief Executive Officer.
 "However, lead drug targets can be screened for resistance profiles much
 earlier in the development phase, and assays can also be applied in early
 stage drug discovery.  The market potential here is significantly larger than
 the late stage application, and the technology exists to immediately implement
 the assay.  Use of our assays in earlier stages could save pharmaceutical
 companies significant time and money."
     ViroLogic expects to grow the pharmaceutical segment of its business by
 applying its technology and expertise to other serious viral diseases where
 resistance is a key obstacle to treatment.
     "The growing number of hepatitis therapies in development also presents a
 very attractive opportunity, which we are proactively targeting," added Young.
 "ViroLogic is the only viral resistance company that provides the full range
 of resistance testing used in drug development today and is 'neutral' in that
 it does not develop its own drugs and does not intend to compete with the
 pharmaceutical companies.  These factors make ViroLogic an ideal provider of
 drug discovery and drug development services.  We feel that this is a platform
 we can grow by penetrating the earlier stages of drug discovery and
 development as well as by offering complimentary technologies."
 
     About ViroLogic
     ViroLogic is a biotechnology company advancing the fields of
 individualized medicine and pharmacogenomics, helping to make them realities
 in healthcare around the world today.  The Company discovers, develops and
 markets innovative products to guide and improve treatment of serious viral
 diseases such as AIDS and hepatitis.  Its industry-leading expertise in
 virology, molecular biology, clinical research, engineering, information
 systems, and quality assurance has resulted in technology to assess drug
 resistance and susceptibility in viruses that cause these diseases, which
 affect millions of people worldwide.
     The Company's current products are designed to optimize HIV/AIDS treatment
 regimens, providing physicians with important information to help select
 appropriate drugs for their patients and leading to better outcomes and
 reduced costs.  These products are also being used by nearly every major
 pharmaceutical company working to develop new and improved antiviral
 therapeutics that can be more effective in an increasingly drug-resistant
 environment.
     Certain statements in this press release are forward-looking, including
 statements relating to laboratory testing agreements with pharmaceutical
 companies.  These forward-looking statements are subject to risks and
 uncertainties and other factors, which may cause actual results to differ
 materially from the anticipated results or other expectations expressed in
 such forward-looking statements.  These risks and uncertainties include, but
 are not limited to, whether PhenoSense(TM) and GeneSeq(TM) testing will
 achieve market acceptance, whether payers will authorize reimbursement for our
 products, whether we will be able to expand our sales and marketing
 capabilities, whether we encounter problems or delays in automating our
 process, whether we successfully introduce new products using our
 PhenoSense(TM) technology, whether intellectual property underlying our
 PhenoSense(TM) technology is adequate, whether we are able to build brand
 loyalty, and other risks and uncertainties detailed from time to time in our
 reports to the Securities and Exchange Commission, including our report on
 Form 10-K for the year ended December 31, 2000.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X79238467
 
 SOURCE  ViroLogic, Inc.